Since the first, seminal randomised controlled trial (RCT) in inflammatory bowel disease (IBD) in 1955,1 the central tenets ...

The CEO said last month that the drugmaker had cut costs, revamped its sales operation, and made other big fixes.

Shares of Pfizer Inc. PFE slipped 1.21% to $26.20 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.76% to 5,994.57 and Dow ...

LANSING, MI — Pharmaceutical giant Pfizer has agreed to pay $59.7 million plus interest to settle bribery allegations against ...

Recent health news includes EssilorLuxottica's new FDA-approved Nuance audio glasses, Baxter's CEO José Almeida retiring, Pfizer facing challenges with COVID-related revenue, WHO budget cuts amid U.S ...

Pfizer (PFE) is set to announce Q4 earnings, with analysts expecting a $0.46 profit per share and $17.26B revenue.

California Attorney General Bonta announced a settlement against Pfizer (PFE)-owned Biohaven Pharmaceutical “for submitting false claims to the ...

Michigan has joined the U.S. Department of Justice, 37 other states and Puerto Rico in settling kickback allegations against a Pfizer, Inc. subsidiary. Pfizer has agreed to ...

Merck and Pfizer are heading into fourth quarter earnings with different technical setups, leaving investors unsure of which ...

The colon cancer BRAFF mutation study is one of the first to be initiated under the FDA’s Project FrontRunner.

Pfizer Inc (PFE) stock saw a decline, ending the day at $26.52 which represents a decrease of $-0.39 or -1.45% from the prior close of $26.91. The stock opened at $26.96 and touched a low of $26.42 ...

Pfizer Settles Its Subsidiary’s Kickback Allegations for Nearly $60 Million - Pfizer Inc. agreed to pay over $59,746,277 to ...